Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 4/20 | 0.38 |
| ▸ | CCND1 | P24385 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13498224 | 0.92 | JAK2 (0.40) | BRD4HRH3SCN8ACDK2KDR | |
| SCHEMBL1634851 | 0.91 | BRD4 (0.42) | BRD4HRH3SCN8ACDK2KDR | |
| SCHEMBL1633401 | 0.80 | HRH3 (0.51) | HRH3JAK2 | |
| SCHEMBL1634177 | 0.79 | CDK2 (0.47) | BRD4HRH3CDK2KDRCCNE1 | |
| SCHEMBL1633499 | 0.79 | BRD4 (0.46) | BRD4CDK2KDRCDK4CCND1 | |
| SCHEMBL1633174 | 0.79 | JAK2 (0.45) | BRD4SCN8ACDK2KDRCDK4 | |
| SCHEMBL1632381 | 0.77 | BRD4 (0.38) | BRD4SCN8ACDK2KDRJAK2 | |
| SCHEMBL1631022 | 0.76 | JAK2 (0.54) | CDK2KDRCDK4CCND1JAK2 | |
| SCHEMBL13498359 | 0.75 | PDE5A (0.45) | CDK2KDRCDK4CCND1JAK1 | |
| SCHEMBL1633855 | 0.75 | JAK1 (0.48) | CDK2KDRCDK4CCND1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | BRD4 268/4885HRH3 3514/4885SCN8A 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.